Guillain-Barré and COVID; Head-to-Head Alzheimer’s Blood Tests; Fastball EEG

One in five people with Guillain-Barré syndrome (GBS) had a preceding SARS-CoV-2 infection, but whether COVID-19 increased GBS risk wasn’t clear. (Brain)

The MIND diet was linked to better cognitive functioning in older adults with brain pathology, suggesting it may promote cognitive resilience. (Journal of Alzheimer’s Disease)

Plasma assays using certain mass spectrometry methods performed better than most immunoassays in detecting brain amyloid pathology in early Alzheimer’s disease. (JAMA Neurology)

People with neurologic conditions were more likely to have elevated adverse childhood experience scores than the general U.S. population. (Neurology Clinical Practice)

Fastball, a new EEG method to measure recognition memory, picked up small, subtle changes in brain waves when people remembered an image and discriminated Alzheimer’s patients from healthy controls, a small study showed. (Brain)

Low-dose levetiracetam (Keppra) improved executive function and spatial memory in Alzheimer’s patients who had seizures or subclinical epileptiform activity. (JAMA Neurology)

Humana filed suit against Biogen, saying the drug company sought to boost sales of natalizumab (Tysabri), interferon beta-1a (Avonex) and dimethyl fumarate (Tecfidera) by baiting multiple sclerosis patients with free sample drugs and then encouraging them to get Medicare benefits and illegally paying their copays. (Bloomberg)

Verdiperstat, an investigational myeloperoxidase enzyme inhibitor, did not statistically differentiate from placebo on the primary efficacy measure or key secondary measures in a phase III trial of multiple system atrophy, Biohaven said.